Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Related Citations for PubMed (Select 1359846)


The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, et al.

Ann Intern Med. 1990 May 15;112(10):727-37.


Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)

Mulder JW, Cooper DA, Mathiesen L, Sandström E, Clumeck N, Gatell JM, French M, Donovan B, Gray F, Yeo JM, et al.

AIDS. 1994 Mar;8(3):313-21. Erratum in: AIDS 1994 Jun;8(6):following 859.


Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L.

Ann Intern Med. 1997 Mar 1;126(5):355-63.


A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richman DD, Fuchs E, et al.

N Engl J Med. 1990 Oct 11;323(15):1009-14.


A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.

Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS, et al.

N Engl J Med. 1995 Aug 17;333(7):401-7.


Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.

Mannucci PM, Gringeri A, Savidge G, Gatenby P, Laurian Y, Pabinger-Fasching I, Martinez-Vazquez JM, Hessey EW, Steel HM.

Br J Haematol. 1994 Jan;86(1):174-9.


Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.

Goldstein G, Conant MA, Beall G, Grossman HA, Galpin JE, Blick G, Calabrese LH, Hirsch RL, Fisher A, Stampone P, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):279-88.


The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, et al.

N Engl J Med. 1987 Jul 23;317(4):192-7.


Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.

Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD, et al.

Arch Intern Med. 1995 May 8;155(9):961-74. Erratum in: Arch Intern Med 1995 Nov 13;155(20):2255.


AZT toxicity and AIDS prophylaxis: is AZT beneficial for HIV+ asymptomatic persons with 500 or more T4 cells per cubic millimeter?

Zaretsky MD.

Genetica. 1995;95(1-3):91-101. Review. Erratum in: Genetica 1995;96(3):307.


Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.

Merigan TC, Amato DA, Balsley J, Power M, Price WA, Benoit S, Perez-Michael A, Brownstein A, Kramer AS, Brettler D, et al.

Blood. 1991 Aug 15;78(4):900-6.


Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J, et al.

N Engl J Med. 1993 Jul 29;329(5):297-303.


A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, et al.

N Engl J Med. 1992 Feb 13;326(7):437-43.


Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial.

Marroni M, Gresele P, Landonio G, Lazzarin A, Coen M, Vezza R, Sinnone MS, Boschetti E, Nosari AM, Stagni G, Nenci GG, Pauluzzi S.

Ann Intern Med. 1994 Sep 15;121(6):423-9.


Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials.

Jacobson MA, Gundacker H, Hughes M, Fischl M, Volberding P.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):45-52.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk